Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Biophytis S.A.

Apply for FDA Emergency Use Authorization and EMA Conditional Marketing Authorisation for Sarconeos

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
26 Feb 2021
Due
30 Jun 2021
Checked
26 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“the Company anticipates applying for Emergency Use Authorization from FDA, and Conditional Market Approval from EMA in Q2 2021”

What we found

Evidence strength A What the grades mean

The July 1, 2021 6-K moved the expected EUA/CMA filings from Q2 2021 to by year-end 2021; no filing was reported as made by the deadline.

  • A
    Biophytis S.A. 6-K filed 2021-07-01 Regulatory filing · published 1 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “Top line results for the full study are now expected in Q4 2021, in view of a potential filing for Emergency Use Authorization and Conditional market Approval applications respectively with FDA and EMA by year end.” ✓ confirmed on the page
  • A
    Biophytis S.A. 6-K filed 2021-07-01 Regulatory filing · published 1 Jul 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “These contracts were signed in preparation of the potential filing of the product in COVID-19 for Emergency Use Authorization with FDA, or Conditional Marketing Authorization with EMA.” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Regulatory other
Indicative materiality
Medium rules
Action
Apply
Deliverable
FDA Emergency Use Authorization and EMA conditional approval applications
Where
United States and European Union
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
Medium
Conditional
Yes: subject to any COVID-19 related delays
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Biophytis S.A.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C768946-024743 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.